查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1610271

多囊性腎病治療藥物市場：按類型、治療、診斷、分銷管道和最終用戶分類 - 2025-2030 年全球預測

Polycystic Kidney Disease Drugs Market by Type (ADPKD, ARPKD), Treatment (Medication, Surgery), Diagnosis, Distribution Channels, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年多囊性腎治療藥物市值為5,1956萬美元，預計2024年將達5,5,657萬美元，複合年成長率為5.95%，到2030年將達7億美元。

多囊性腎病變(PKD) 治療市場研究透過專注於用於治療PKD 的藥物解決方案來分析其範圍和定義，我正在捕獲這種疾病，這是一種以腎臟中生長大量囊腫為特徵的遺傳性疾病。對 PKD 藥物的需求源於 PKD 盛行率的增加和治療方法的缺乏，以及控制症狀和減緩疾病進展的需要。主要用途是控制高血壓和抑制囊腫形成，針對發生率高於其他類型的常染色體顯性多囊腎（ADPKD）患者。一系列最終用途包括醫院、專科診所和進行治療和藥物臨床試驗的研究實驗室。

主要市場統計
基準年[2023] 51956萬美元
預計年份 [2024] 55657萬美元
預測年份 [2030] 77882萬美元
複合年成長率（%） 5.95%

關鍵的成長要素包括基因研究的進步、提高早期診斷意識以及增加對新療法研發的投資。市場開拓機會比比皆是，包括整合精準醫療來個人化治療方法，以及與生技公司合作加速藥物開發。為了利用這些優勢，公司應該投資基因組技術並與學術機構建立合作關係以進行突破性研究。

市場開拓面臨的挑戰包括藥物開發的高成本、嚴格的法規以及限制患者依從性的潛在副作用。此外，無症狀病例的存在可能會阻礙早期的市場滲透策略，因為診斷主要是在後期進行的。利用人工智慧進行預測分析的創新治療可以促進更有針對性的治療方法，透過專注於聯合治療來提高治療效果，並擴大治療領域。

PKD 治療市場的性質是動態的，跨國製藥公司和新興生物技術公司發揮關鍵作用。為了持續的業務成長，公司應該追求多元化的產品線，並專注於直接解決囊腫生長的藥物，而不僅僅是控制症狀。加強策略聯盟和以患者為中心的方法對於克服市場挑戰和抓住快速成長機會至關重要。

市場動態：快速發展的多囊性腎治療市場的關鍵市場洞察

多囊性腎病藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 人群中慢性腎臟病的盛行率
    • 加強多囊性腎病變的合作與研究
    • 各國醫療保健支出增加
  • 市場限制因素
    • 製造複雜性
  • 市場機會
    • 市場參與者開拓先進藥物
    • 策略聯盟投資與產能擴張
  • 市場挑戰
    • 品管問題

波特五力戰略工具駕馭多囊性腎病藥物市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對多囊性腎病藥物市場的影響

外部宏觀環境因素在塑造多囊性腎病治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解多囊性腎治療藥物市場的競爭狀況

對多囊性腎病治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣多囊性腎病變治療市場供應商的績效評估

FPNV 定位矩陣是評估多囊性腎病變治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為多囊性腎治療藥物市場的成功指明道路

對於希望加強在全球市場的影響力的公司來說，對多囊性腎病治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中慢性腎臟病的盛行率
      • 加強多囊性腎病變的合作與研究
      • 經濟體中的醫療成本增加
    • 抑制因素
      • 與生產相關的複雜性
    • 機會
      • 市場參與企業開發先進藥物
      • 策略聯盟和投資以擴大產能
    • 任務
      • 品管問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章多囊腎治療藥物市場：依類型

  • ADPKD
  • ARPKD

第7章依治療分類的多囊性腎治療藥物市場

  • 藥物治療
  • 外科手術

第8章 多囊腎疾病診斷治療藥物市場

  • 電腦斷層掃描
  • MRI
  • 超音波

第9章按通路分類的多囊性腎治療藥物市場

  • 醫院藥房
  • 零售藥房

第 10 章 多囊性腎病治療藥物市場：依最終使用者分類

  • 醫院/診所
  • 專科診所

第11章 北美和南美多囊性腎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區多囊性腎治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲多囊性腎病治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Centessa Pharmaceuticals Limited
  • Dr. Reddys Laboratories Ltd.
  • Galapagos NV
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XORTX Therapeutics Inc.
Product Code: MRR-62667ADF9FE1

The Polycystic Kidney Disease Drugs Market was valued at USD 519.56 million in 2023, expected to reach USD 556.57 million in 2024, and is projected to grow at a CAGR of 5.95%, to USD 778.82 million by 2030.

Polycystic Kidney Disease (PKD) drugs market research captures the scope and definition by focusing on medication solutions used for managing PKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys. The necessity for PKD drugs is driven by the increasing prevalence of the disease and the lack of curative treatments, necessitating management of symptoms and slowing disease progression. Applications primarily involve the control of hypertension and reduction of cyst formation, targeting patients with autosomal dominant PKD (ADPKD) due to its higher incidence compared to other types. End-use scope notably includes hospitals, specialty clinics, and research organizations where treatment and drug trials are conducted.

KEY MARKET STATISTICS
Base Year [2023] USD 519.56 million
Estimated Year [2024] USD 556.57 million
Forecast Year [2030] USD 778.82 million
CAGR (%) 5.95%

Key growth influencers include advancements in genetic research, heightened awareness leading to earlier diagnosis, and rising investments in R&D for novel therapeutics. The market is ripe with opportunities such as the integration of precision medicine to individualize treatment regimens and collaboration with biotechnology firms to accelerate drug development. To harness these, firms should invest in genomic technologies and establish partnerships with academic institutions for breakthrough research.

Challenges constricting market expansion encompass the high cost of drug development, stringent regulatory pathways, and potential side effects limiting patient compliance. Additionally, the existence of asymptomatic cases can impede early market penetration strategies, as diagnosis occurs predominantly at later stages. Innovating through AI for predictive analytics can facilitate more targeted treatment approaches, and focusing on combination therapies may enhance treatment efficacy and widen the therapeutic landscape.

The nature of the PKD drugs market is dynamic, with multinational pharmaceutical companies and emerging biotechnology firms playing significant roles. For sustained business growth, companies should pursue diversified pipelines, emphasizing drugs that not only manage symptoms but also address cyst growth directly. Enhancing strategic alliances and patient-centric approaches will be pivotal in overcoming both market challenges and seizing burgeoning opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Polycystic Kidney Disease Drugs Market

The Polycystic Kidney Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic kidney disorders among population
    • Rising collaboration and research on polycystic kidney disease
    • Growing healthcare expenditure in economies
  • Market Restraints
    • Complexities associated with the production
  • Market Opportunities
    • Development of advanced medications by market players
    • Strategic alliances and investment for capacity expansion
  • Market Challenges
    • Issues pertaining to quality management

Porter's Five Forces: A Strategic Tool for Navigating the Polycystic Kidney Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Polycystic Kidney Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Polycystic Kidney Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Polycystic Kidney Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Polycystic Kidney Disease Drugs Market

A detailed market share analysis in the Polycystic Kidney Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Polycystic Kidney Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Polycystic Kidney Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Polycystic Kidney Disease Drugs Market

A strategic analysis of the Polycystic Kidney Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Kidney Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Apotex Inc., AstraZeneca PLC, Centessa Pharmaceuticals Limited, Dr. Reddys Laboratories Ltd., Galapagos NV, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Polycystic Kidney Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across ADPKD and ARPKD.
  • Based on Treatment, market is studied across Medication and Surgery.
  • Based on Diagnosis, market is studied across CT Scan, MRI, and Ultra Sound.
  • Based on Distribution Channels, market is studied across Hospital Pharmacy and Retail Pharmacy.
  • Based on End-User, market is studied across Hospital & Clinics and Speciality Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic kidney disorders among population
      • 5.1.1.2. Rising collaboration and research on polycystic kidney disease
      • 5.1.1.3. Growing healthcare expenditure in economies
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with the production
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of advanced medications by market players
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Issues pertaining to quality management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Kidney Disease Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. ADPKD
  • 6.3. ARPKD

7. Polycystic Kidney Disease Drugs Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Surgery

8. Polycystic Kidney Disease Drugs Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. CT Scan
  • 8.3. MRI
  • 8.4. Ultra Sound

9. Polycystic Kidney Disease Drugs Market, by Distribution Channels

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Retail Pharmacy

10. Polycystic Kidney Disease Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospital & Clinics
  • 10.3. Speciality Clinics

11. Americas Polycystic Kidney Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Polycystic Kidney Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Apotex Inc.
  • 3. AstraZeneca PLC
  • 4. Centessa Pharmaceuticals Limited
  • 5. Dr. Reddys Laboratories Ltd.
  • 6. Galapagos NV
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Otsuka Pharmaceutical Co., Ltd.
  • 11. Reata Pharmaceuticals Inc.
  • 12. Sanofi S.A.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. XORTX Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ADPKD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ARPKD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ULTRA SOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023